Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALDOSE-2: IMU-838 (vidofludimus calcium) in active Crohn's disease
2018-001895-39Phase 2Terminated
- Sponsor
- Immunic Therapeutics
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vidofludimus calcium in Crohn's disease (4 arms), sponsored by Immunic Therapeutics. Primary endpoints: Symptomatic remission based on CDAI PRO-2 (stool frequency and abdominal pain) and Endoscopic improvement. Started Mar 2019; status: terminated.
02
Drugs
vidofludimus calcium
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2018-001895-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001895-39.